18 results about "Vulnerable plaque" patented technology

The invention discloses a radioactive diagnosis medicine for targeting OPN as well as a preparation method and application of the radioactive diagnosis medicine. The radioactive diagnosis medicine comprises linear polypeptide and radionuclide, wherein the linear polypeptide is composed of 20 L-type amino acids and one D-type amino acid, and the radionuclide marks the linear polypeptide through a bifunctional chelating agent; the sequence of the linear polypeptide is as shown in SEQ ID NO. 1. In vivo, radionuclides in the medicine are concentrated to an atherosclerotic vulnerable plaque part through the targeting effect of the amino acid linear polypeptide, and imaging diagnosis is carried out on the atherosclerotic vulnerable plaque by utilizing a positron emission computed tomography technology of nuclear medicine.

The application discloses a kind of intravascular virtual stent size determination method, it is related to medical image processing technical field.The method comprises the following steps: obtaining the OCT image group in the polar coordinate of target blood vessel section;Determine the IPA value of each OCT image in the OCT image group;Determine the preset value, based on the IPA value and the preset value, the EEL recognition state in the OCT image is configured as the first state and the second state;In the case where EEL is in the first state, EEL is enhanced and repaired based on the deep learning model;In the case where EEL is in the second state, EEL is completed and reconstructed based on the completion subnetwork, and the confidence is obtained;According to the comprehensive loss function, the size of the virtual stent is determined.The application improves the clinical consistency of FFR prediction: since the planning of virtual stent considers vulnerable plaque distribution, the predicted stent position is closer to the safe position that the doctor will actually choose during surgery.Therefore, the calculated virtual FFR value has higher consistency with the actual measured FFR value after surgery, and the clinical guidance value of the system is improved.

A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for diagnosing, preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

The present application relates to the field of food, health care products and medicine, and specifically relates to a purslane oral composition for regulating blood lipid and resisting atherosclerosis, and a preparation method and application thereof. The present application takes purslane extract, galangal extract and borneol as core components, and realizes the synergistic effects of lipid regulation, anti-inflammation, reduction of plaque area, stabilization of vulnerable plaque, mild anti-thrombus and myocardial protection through scientific proportioning. The bioavailability is significantly improved by combining the tongue sublingual absorption of borneol and the mucosal penetration of galangal volatile oil. The composition has comprehensive targets, definite effects and good safety, and can be made into oral dosage forms such as buccal tablets, dripping pills and oral disintegrating tablets, and is suitable for daily oral care of cardiovascular sub-healthy people.

A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

The invention relates to a plaque analysis method and system and a storage medium. The method comprises the steps of obtaining a blood vessel image; the blood vessel image comprises a plaque structure; segmenting a target object in the blood vessel image to obtain attribute information of the target object; the target object comprises a plaque structure and a blood vessel structure; the attribute information comprises at least one of a reconstruction index, an eccentricity index, a plaque load, a calcification integral and a probability index of the plaque structure; the probability index is used for evaluating the probability that the plaque structure is a vulnerable plaque; and performing type analysis on the plaque structure according to the attribute information of the target object to obtain an analysis result. According to the embodiment of the invention, more comprehensive and accurate attribute information of the target object can be determined, so that the plaque structure can be subjected to type analysis according to the more comprehensive and accurate attribute information of the target object, and a more accurate analysis result is obtained. Therefore, the accuracy of analyzing the plaque in the blood vessel can be improved.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating atherosclerosis, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises the following raw material components in parts by mass: 8-10 parts of Guangxi curcuma zedoary, 8-12 parts of peach kernels, 8-12 parts of cassia twigs, 8-12 parts of poria cocos, 25-35 parts of raw astragalus membranaceus, 8-12 parts of moutan bark, 8-12 parts of red peony roots, 10-20 parts of fructus mali, 10-15 parts of herba lycopi and 25-35 parts of oysters. The traditional Chinese medicine composition can improve the lesion degree of atherosclerosis, reduce the blood fat level and reduce the generation of atheromatous plaques, thereby improving the atherosclerosis; meanwhile, the traditional Chinese medicine composition has an anti-AS effect in the aspects of stabilizing vulnerable plaques, promoting reverse transport of cholesterol, adjusting energy metabolism and water metabolism of mitochondria, resisting inflammation and resisting oxidative stress.

A method and apparatus for identifying a vulnerable coronary plaque based on a multimodal large language model (MM-LLM) are provided. The method includes: acquiring a target 3D coronary computed tomography angiography (CCTA) image and a target straightened curved planar reformation (SCPR) image; acquiring plaque mask information of a blood vessel based on the target SCPR image; acquiring basic plaque data based on the plaque mask information; acquiring fluid dynamics data of each plaque area based on the SCPR image; acquiring basic clinical testing information; standardizing above image data, structural data, and textual data separately, and performing, by a regression mapping network, feature fusion to acquire a first fusion feature; acquiring a trained vulnerable plaque identification LLM; and inputting the first fusion feature into the vulnerable plaque identification LLM to acquire an identification result. The method solve problems of poor single-image feature expression ability and low identification performance in traditional technologies.

The invention relates to the field of biological medicine, in particular to AS vulnerable plaque treatment nanoparticles and a preparation method and application thereof.The nanoparticles comprise hollow mesoporous manganese dioxide nanospheres, and the manganese dioxide nanospheres are loaded with 5 alpha-hydroxycostus acid and perfluoropentane; the manganese dioxide nanosphere is coated with an M2 type macrophage-liposome hybrid membrane, and VLA-4 is expressed on the M2 type macrophage-liposome hybrid membrane. By means of the scheme, normalization of new vessels in plaques is achieved, then the plaques are stabilized, and the problem that treatment cannot be conducted from the perspective of normalization of the new vessels in the prior art is solved.

The application discloses an arterial plaque detection method based on thermoacoustic imaging technology. The method processes the collected ultrasonic signals, and the results are reflected on two different channels in software. After processing by an image reconstruction module, a thermoacoustic imaging graph and a photoacoustic imaging graph are reconstructed, and a vulnerable plaque part is automatically identified. Through mutual verification and self-examination of the processing results of the two kinds of imaging graphs, a suspected vulnerable plaque part is marked and position inversion is performed, necessary basic information is provided for classification and treatment of the vulnerable plaque; the combination of the two imaging modes can provide physiological indexes; the transmitted data is processed in the image reconstruction module through a network, and the application in health prevention and disease diagnosis is met.

This invention specifically discloses a photoacoustic nanorobot, its preparation method, and its applications, relating to the field of atherosclerotic plaque imaging technology, and particularly to a photoacoustic imaging agent for atherosclerotic plaques. The photoacoustic nanorobot provided by this invention uses the plaque's unique high-lipid environment as a signal "switch," targets unwinding collagen—which is directly related to plaque mechanical stability—as the imaging target, and combines active chemotactic movement capabilities to achieve targeted penetration and heterogeneity analysis, thereby realizing specific enhanced imaging of vulnerable plaques.

The application discloses a vulnerable plaque detection method and related equipment, and relates to the medical identification field, and mainly aims to solve the problem that there is no method for accurately identifying vulnerable plaques in a blood vessel wall image. The method comprises the following steps: constructing an imageomics model based on the plaque characteristics of at least two test samples through plain scanning and enhanced 3D HRMR-VWI image; determining a fusion prediction model based on a traditional model and the imageomics model; and determining the vulnerable plaque of a target sample based on the fusion prediction model. The application is used in the vulnerable plaque detection process.

The invention relates to the technical field of biomedicine, in particular to a double-target probe for evaluating the vulnerability of artery plaques and application of the double-target probe. The invention provides a double-target probe and application thereof in detection of vulnerable plaque markers MPO and MMP-9, the double-target probe has high specificity, accuracy and sensitivity, can provide multi-dimensional diagnostic information for vulnerable plaque generation, and can be used for detecting vulnerable plaque markers such as MPO and MMP-9. The plaque instability is reflected from the structural level, and the plaque inflammatory oxidation degree is reflected from the inflammation level; compared with a single marker diagnosis result, the double-target probe provided by the invention not only can improve the utilization rate of a detected sample, but also has the technical advantage of noninvasive and nondestructive detection.

According to the application of the serological biomarker in preparation of the vulnerable plaque diagnostic kit, the serological biomarker comprises sTREM2. Human peripheral blood serum is collected, and the concentration of soluble myeloid cell triggered receptor 2 (sTREM2) in the serum is determined by using an enzyme-linked immunosorbent assay (ELISA) kit or an equivalent immunoassay method, so that early discovery and (dynamic) monitoring of vulnerable plaques are realized. Through verification, the sTREM2 is suitable for being used as a diagnosis and prediction marker of vulnerable plaque related diseases, and guidance is provided for further clinical diagnosis (such as OCT / IVUS) and treatment.

This invention discloses a compound traditional Chinese medicine preparation for early intervention in atherosclerotic plaques and its preparation method. The compound traditional Chinese medicine preparation comprises main ingredients and excipients. The main ingredients include a blood-activating and stasis-removing group, a phlegm-resolving and turbidity-reducing group, and a qi-tonifying and spleen-strengthening group. The blood-activating and stasis-removing group comprises the following ingredients in weight percentage: Panax notoginseng 1-3 parts, Salvia miltiorrhiza 12-18 parts, and Gentiana scabra 10-12 parts. The phlegm-resolving and turbidity-reducing group comprises the following ingredients in weight percentage: Trichosanthes kirilowii 40-25 parts, Allium macrostemon 25-15 parts, Ligusticum chuanxiong 6-12 parts, Pinellia ternata 5-8 parts, Citrus reticulata 6-12 parts, and Acorus tatarinowii 6-12 parts. The qi-tonifying and spleen-strengthening group comprises the following ingredients in weight percentage: Poria cocos 12-18 parts, Codonopsis pilosula 12-18 parts, and Glycyrrhiza uralensis 5-8 parts. The weight ratio of the blood-activating and stasis-removing group, the phlegm-resolving and turbidity-reducing group, and the qi-tonifying and spleen-strengthening group is 1-5:1-5:1-5. It has the effect of treating both phlegm and blood stasis, and can significantly stabilize vulnerable atherosclerotic plaques. It can be used to treat atherosclerotic cardiovascular diseases and has the advantages of definite curative effect, no toxic side effects, low cost, and easy promotion and application.

The invention relates to an application of Podocan in predicting a coronary blood vessel vulnerable plaque model. Plasma proteomics, machine learning and mechanism research are combined to discover and verify that Podocan is used as a biomarker and a regulatory factor of plaque stability. On the one hand, as a detection marker, the marker is beneficial to predicting and diagnosing the vulnerability of atherosclerotic plaques, performing more accurate risk stratification on patients, and taking more positive preventive measures or implementing early intervention on patients possibly suffering from acute coronary syndromes. On the other hand, as a plaque stability regulatory factor, the compound has the significance of targeted therapy.

The application provides a cerium-zirconium and arginine nano composite drug targeting an arterial vulnerable plaque microenvironment and preparation and application thereof, including L-arginine, solid cerium-zirconium nanozyme, bone bridge protein short peptide and a liposome carrier. The mass ratio of the L-arginine, the solid cerium-zirconium nanozyme and the bone bridge protein short peptide is 2:5:2, and the mass ratio of the liposome carrier and the total of the three substances is 1:1600-1800. The application innovatively uses a slow-release preparation technology to complete the encapsulation of the cerium-zirconium nanozyme and basic L-arginine, realizes neutralization of a plaque microenvironment, and realizes specific treatment of foam cells through surface modification of bone bridge protein for targeted release of drugs. The compound realizes anti-aging treatment of atherosclerosis, has a small particle size, high biocompatibility, a simple and mature process, low material cost, is stable and reliable, and is a convenient, safe and ideal way for treating AS.

The invention discloses a construction method of an atherosclerotic advanced vulnerable plaque rapid modeling gene mouse, and belongs to the technical field of biology. According to the method, an apolipoprotein E gene (apolipoprotein E, ApoE) knockout mouse which does not need to be subjected to induction and is specifically knocked out from an insulin-like growth factor 1 (IGF1) gene tissue is obtained through a hybridization method and a Cre-LoxP technology. According to the invention, a mononuclear phagocyte system specific knockout IGF1 gene is introduced into an ApoE- / -mouse genome for the first time, the characteristics of two genotypes are combined, and atherosclerotic advanced vulnerable plaque with the characteristics of large lipid core, a large number of inflammatory cells, typical thin fibrous caps, negative vascular remodeling and the like can be formed without induction; and the method is simple and easy to implement and good in repeatability, and the molding time is shortened.